IFN-α induces early lethal lupus in preautoimmune (New Zealand black x New Zealand White)F1 but not in BALB/c mice

被引:205
作者
Mathian, A
Weinberg, A
Gallegos, M
Banchereau, J
Koutouzov, S
机构
[1] Baylor Inst Immunol Res, Dallas, TX 75204 USA
[2] Childrens Hosp, Dept Pathol, Dallas, TX 75235 USA
关键词
D O I
10.4049/jimmunol.174.5.2499
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent studies indicate that IFN-alpha is involved in pathogenesis of systemic lupus erythematosus. However, direct proof that IFN-alpha is not only necessary, but also sufficient to induce lupus pathogenicity is lacking. In this study, we show that in vivo adenovector-mediated delivery of murine IFN-alpha results in preautoimmune (New Zealand Black (NZB) X New Zealand White (NZW))F-1, but not in normal, mice, in a rapid and severe disease with all characteristics of systemic lupus erythematosus. Anti-dsDNA Abs appeared as soon as day 10 after initiation of IFN-alpha treatment. Proteinuria and death caused by glomerulonephritis occurred in all treated mice within, respectively, similar to9 and similar to18 wk, at a time when all untreated (NZB X NZW)F-1 did not show any sign of disease. IFN-alpha in vivo induced an overexpression of B lymphocyte stimulator in circulation at similar levels in both the preautoimmune and the normal mouse strains. All effects elicited by IFN-alpha were dose dependent. (NZB X NZW)F-1 infused with purified murine IFN-alpha also showed acceleration of lupus. Thus, prolonged expression of IFN-alpha in vivo induces early lethal lupus in susceptible animals.
引用
收藏
页码:2499 / 2506
页数:8
相关论文
共 66 条
[51]   Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice [J].
Santiago-Raber, ML ;
Baccala, R ;
Haraldsson, KM ;
Choubey, D ;
Stewart, TA ;
Kono, DH ;
Theofilopoulos, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :777-788
[52]   HETEROGENEITY OF IMMUNE COMPLEX-DERIVED ANTI-DNA ANTIBODIES ASSOCIATED WITH LUPUS NEPHRITIS [J].
SASAKI, T ;
HATAKEYAMA, A ;
SHIBATA, S ;
OSAKI, H ;
SUZUKI, M ;
HORIE, K ;
KITAGAWA, Y ;
YOSHINAGA, K .
KIDNEY INTERNATIONAL, 1991, 39 (04) :746-753
[53]  
SERGIESCU D, 1979, BIOMED EXPRESS, V31, P48
[54]   From T to B and back again: positive feedback in systemic autoimmune disease [J].
Shlomchik, MJ ;
Craft, JE ;
Mamula, MJ .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (02) :147-153
[55]   Tolerogenic dendritic cells [J].
Steinman, RM ;
Hawiger, D ;
Nussenzweig, MC .
ANNUAL REVIEW OF IMMUNOLOGY, 2003, 21 :685-711
[56]   Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases [J].
Stewart, TA .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (02) :139-154
[57]  
Vallin H, 1999, J IMMUNOL, V163, P6306
[58]  
VONWUSSOW P, 1989, ARTHRITIS RHEUM, V32, P914
[59]   Delineating the genetic basis of systemic lupus erythematosus [J].
Wakeland, EK ;
Liu, K ;
Graham, RR ;
Behrens, TW .
IMMUNITY, 2001, 15 (03) :397-408
[60]   Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis [J].
Waters, ST ;
McDuffie, M ;
Bagavant, H ;
Deshmukh, US ;
Gaskin, F ;
Jiang, C ;
Tung, KSK ;
Fu, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (02) :255-264